
AlphaRose Therapeutics
OperatingAlphaRose Therapeutics Inc
Biotech · Austin, TX
Alpha Rose Therapeutics, born from a father's love for his daughter, is pioneering personalized medicine at scale for children with genetic diseases. Our innovative approach rapidly develops and commercializes treatments for patients ignored by large pharma. With over $1 million in funding, our lead product, Rosiphersen, is advancing towards a clinical trial, backed by the NCATS TRND program acceptance and led by a passionate, experienced team. AlphaRose Therapeutics is an early-stage biotechnology company, and its treatments, including Rosiphersen, are still in development and have not yet been approved for clinical use.
Financials
FY2022–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Fundraising history
Team
5 people
Entrepreneur, singer-songwriter, and advocate for rare disease treatments. He founded The To Cure A Rose Foundation and Everlum Bio, a rare disease CRO, after his daughter's diagnosis. McPherson leverages his network and experience in the music industry to drive drug development for personalized genetic treatments. He is a father, outdoor enthusiast, and sought-after speaker on rare diseases.

Masako brings 30 years of commercial, general management and operational leadership experience in the biopharmaceutical industry with a strong focus on introducing innovative rare disease therapies worldwide across multiple therapeutic areas. She has held several international and global senior leadership roles at Amylyx, Alnylam, Novelion, Genzyme and Genetics Institute. Throughout her tenure, she has had the honor and privilege of developing and launching over 20 innovative transformative medicines for the rare disease and oncology communities globally. She continues to be passionate about making a significant difference in patients' lives, while always keeping patients and science at the center of what we do.

Co-Founder and Executive Chairman of Chrysalis Genetics. He serves on the boards of several biopharmaceutical companies and is active in venture capital funding. With a Ph.D. in chemistry from MIT, Dr. Walts has extensive experience in business development, research, and general management, particularly during his 27-year tenure at Genzyme. He is a respected advisor and mentor in the life sciences industry.

Passionate advocate for personalized medicine. She leads the Termeer family office and serves on numerous boards, including PIC Therapeutics, BioVentures for Global Health, Harvard Medical School, and Massachusetts General Hospital. With her late husband, Henri Termeer, she established a center for targeted therapies at Mass General, furthering their commitment to advancing treatments for rare diseases.

Lance Hirsch is a computer programmer and Scoutmaster from Boerne, Texas. He has a passion for technology and a strong commitment to community service. Lance has over 15 years of experience as a software developer, working on a variety of projects for companies of all sizes. He is known for his strong technical skills and ability to deliver results on time and within budget. Lance is a graduate of the University of Texas at Austin, where he earned a degree in computer science. He is also a certified Scrum Master and Agile Certified Practitioner. Lance is married and has two children. He enjoys spending time with his family, hiking, camping, and fishing.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form C-UOct 6, 20250002051498-25-000002EDGAR
- Form C/AAug 27, 20250001665160-25-001394EDGAR
- Form C/AAug 14, 20250001665160-25-001371EDGAR
- Form C/AJun 17, 20250001665160-25-001223EDGAR
- Form C-ARApr 29, 20250001665160-25-000789EDGAR
- Form C/AMar 18, 20250001665160-25-000427EDGAR
- Form CJan 29, 20250001665160-25-000154EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.